Conference TEHI, November 07-08-Samarkhand, Uzbekistan
Pillars of Innovation: WUST Research Review-2025
Conference-AII, October 28-30, Washington D.C, United States
WUST Research Center
Conference IEEE i-COSTE December 02-04, 2025
Conference on Business Innovation-ICBIID January, 2026
IJCACI 2026 Conference, July 24, Alexandria
Conference TEHI, November 07-08-Samarkhand, Uzbekistan
Pillars of Innovation: WUST Research Review-2025
Conference-AII, October 28-30, Washington D.C, United States
WUST Research Center
Conference IEEE i-COSTE December 02-04, 2025
Conference on Business Innovation-ICBIID January, 2026
IJCACI 2026 Conference, July 24, Alexandria
Conference TEHI, November 07-08-Samarkhand, Uzbekistan
Pillars of Innovation: WUST Research Review-2025
Conference-AII, October 28-30, Washington D.C, United States
WUST Research Center
Conference IEEE i-COSTE December 02-04, 2025
Conference on Business Innovation-ICBIID January, 2026
IJCACI 2026 Conference, July 24, Alexandria
Conference TEHI, November 07-08-Samarkhand, Uzbekistan
Pillars of Innovation: WUST Research Review-2025
Conference-AII, October 28-30, Washington D.C, United States
WUST Research Center
Conference IEEE i-COSTE December 02-04, 2025
Conference on Business Innovation-ICBIID January, 2026
IJCACI 2026 Conference, July 24, Alexandria
Latest Research at the Intersection of STEM & Business
This analysis models levelized cost of electricity (LCOE) for SMRs across three regulatory regimes and identifies tipping points for commercial deployment. We find that factory manufacturing at >8 units/year reduces capex by 28% versus first-of-a-kind builds, with strongest market fit in industrial microgrids.
We report results from a 6-month federated learning deployment across 14 tier-2 banks. The model achieved 91.3% recall on novel fraud patterns with zero raw data sharing. Latency increased 12ms per transaction. We discuss regulatory approvals, model governance, and ROI at $2.1M annual loss prevention per bank.
NovaGraft reduced COGS for autologous CAR-T from $180k to $42k per dose via closed-system automation and distributed manufacturing. We detail facility design, regulatory strategy with FDA, and Series B terms. Key lesson: treat the bioreactor like a software release pipeline.
This report outlines IP bundling, field-of-use licensing, and royalty structures used to commercialize a 120-km QKD link. We provide a template for national lab → telecom deals, including export control review steps and indemnification clauses that accelerated time-to-contract by 5 months.
Based on interviews with 11 providers and legal counsel, we estimate initial compliance costs of €4.2M-€11.7M for GPAI models, driven by data governance and red-teaming. SMEs face disproportionate burden. We propose tiered obligations and shared audit infrastructure.